Contribute Try STAT+ Today

Rise and shine, everyone, another intense day is on the way. The world seems to be spinning faster than usual, yes? So what better way to cope with the chaos than to brew a few cups of stimulation. This is our standard default, as some of you know, but why mess with a time-tested formula? Feel free to join us. No prescription is required, you may recall. And now, on with the show. Here are a few tidbits to get you going. Hope your day is manageable and you stay healthy.

The World Health Organization plans to launch a multiarm, multicountry clinical trial for potential coronavirus therapies, part of an aggressive effort to jumpstart the global search for drugs to treat Covid-19, STAT reports. Four drugs or drug combinations already licensed and used for other illnesses will be tested, and 10 countries have already indicated they will take part in the trial. The four drugs or combinations will be compared to standard of care — the regular support now used by hospitals treating these patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.